Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have opened up a new venue of advanced cancer immunotherapy. However, hyperprogressive disease (HPD) induced by PD-1/PD-L1 inhibitor...

Full description

Bibliographic Details
Main Authors: Li-ping Zhao, Jun-hu Hu, Die Hu, Hao-jie Wang, Chang-gang Huang, Ru-hua Luo, Zhao-huang Zhou, Xin-yun Huang, Tian Xie, Jian-shu Lou
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
HPD
PD-1/PD-L1 inhibitors
Cancer immunotherapy
Biomarkers
Coping strategies
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222003389

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222003389

Similar Items